Tempus
PROVIDERS
LIFE SCIENCES
PATIENTS
OUR PLATFORM
ORDER A TEST
Log In
Contact Us
Menu
Tempus
ORDER A TEST
Log In
Contact Us
Providers
Oncology
Neurology & Psychiatry
Infectious Disease
Cardiology
Academic & Research
EMR Integration
Life Sciences
Sequencing
Companion Diagnostics
Clinical Trial Solutions
Data Collaborations
AI Applications
Biological Modeling
Patients
Oncology Patients
Neurology Patients
Infectious Disease Patients
Our Platform
Genomic Profiling
Clinical Trial Matching
Companion Diagnostics
Multi-Omics
Tempus ONE
Infectious Disease
About Us
Our Team
Careers
Culture
Resources
Publications
News
Blog
Resources
Publications
Keyword search
Filter By
Oncology
Infectious Disease
Cardiology
Neuro/Psych
04/13/2021
Oncology
Synthetic Lethality-Mediated Precision Oncology via the Tumor Transcriptome
04/03/2021
Infectious Disease
Early Introductions and Transmission of SARS-CoV-2 Variant B.1.1.7 in the United States
03/17/2021
Oncology
Non-secretory Multiple Myeloma With Unusual TFG-ALK Fusion Showed Dramatic Response to ALK Inhibition
03/10/2021
Oncology
Transferring Diagnostic and Prognostic Molecular Models Across Technological Platforms
03/10/2021
Oncology
Incidence of Molecular Alterations in KRAS and Other Known Cancer Genes in Patients With Pancreatic Cancer Assessed With a Commercial Genomic Profiling Panel Compared to TCGA Results
03/10/2021
Oncology
Characterizing Differences in Checkpoint Inhibitor Biomarkers in a Real-world Cohort of Stage III and IV Non-small Cell Lung Cancer Patients
03/10/2021
Oncology
Genomic Characterization and Monitoring Molecular Response to Treatment in African American (AA) Advanced Prostate Cancer (PC) Patients (Pts) via Next-Generation Sequencing (NGS): Real-world Experience in a Safety Net Hospital Oncology Clinic
03/10/2021
Oncology
Evaluating Clinical Features and Prognostic Factors Associated With Response to Immune Checkpoint Blockade in mNSCLC Patients
03/10/2021
Oncology
Comprehensive Validation of RNA Sequencing for Clinical NGS Fusion Genes and RNA Expression Reporting
03/10/2021
Oncology
Cytotoxic CD4+ T Cells Contribute to Anti-tumor Immune Responses in NSCLC
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21